Amantadine
GOCOVRI
Influenza A M2 Protein Inhibitor
NADAC/unit
$0.0508
No Shortage
Tier 1: 72.3%
PA Req: 9.1%
19 Manufacturers
22 ANDAs
INDICATIONS AND USAGE Amantadine hydrochloride capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus.
vs. brand GOCOVRI: Generic saves up to 99% per unit
Active Shortages
2025-07-23 Discontinuation of the manufacture of the drug product, Upsher-Smith Laboratories, LLC
2025-07-23 Discontinuation of the manufacture of the drug product, Upsher-Smith Laboratories, LLC
2025-07-23 Discontinuation of the manufacture of the drug product, Upsher-Smith Laboratories, LLC
2025-07-23 Discontinuation of the manufacture of the drug product, Upsher-Smith Laboratories, LLC
2025-07-23 Discontinuation of the manufacture of the drug product, Upsher-Smith Laboratories, LLC
Market Intelligence
2026-03-04 Class II Recall: AvKARE
Generic Manufacturers
ALEMBIC PHARMACEUTICALS LTDATHEM HOLDINGS LLCAUROBINDO PHARMA USA INCBIONPHARMA INCCHARTWELL RX SCIENCES LLCHERITAGE PHARMA LABS INCHUMANWELL PURACAP PHARMACEUTICAL WUHAN CO LTDONESOURCE SPECIALTY PTE LTDPHARMACEUTICAL ASSOCIATES INCPHARMOBEDIENT CONSULTING LLCRISING PHARMA HOLDINGS INCRUBICON RESEARCH LTDSANDOZ INCSHREE HARI INTERNATIONAL LLCSTRIDES PHARMA GLOBAL PTE LTDSUPERNUS PHARMACEUTICALS INCUPSHER SMITH LABORATORIES LLCWATSON LABORATORIES INCZHEJIANG JUTAI PHARMACEUTICAL CO LTDZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.